Resources from the same session
Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial
Presenter: Alexander Eggermont
Session: Presidential Symposium 1
Resources:
Abstract
Slides
Invited discussant LBA3
Presenter: Sandro Pignata
Session: Presidential Symposium 1
Resources:
Slides
Invited discussant LBA2
Presenter: Olivier Michielin
Session: Presidential Symposium 1
Resources:
Slides
First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC)
Presenter: Gabriel Hortobagyi
Session: Presidential Symposium 1
Resources:
Abstract
Slides
A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial)
Presenter: Mansoor Raza Mirza
Session: Presidential Symposium 1
Resources:
Abstract
Slides
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.